News headlines about Hutchison China MediTech (NASDAQ:HCM) have trended somewhat positive on Saturday, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Hutchison China MediTech earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.0348801562908 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Hutchison China MediTech (HCM) opened at $38.98 on Friday. The company has a current ratio of 1.84, a quick ratio of 1.73 and a debt-to-equity ratio of 0.09. Hutchison China MediTech has a fifty-two week low of $12.62 and a fifty-two week high of $42.25.
Several analysts recently commented on the stock. BidaskClub upgraded shares of Hutchison China MediTech from a “hold” rating to a “buy” rating in a report on Saturday, December 30th. Canaccord Genuity raised their price target on shares of Hutchison China MediTech to $38.00 and gave the stock a “buy” rating in a report on Monday, October 16th.
Hutchison China MediTech Company Profile
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.
Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.